Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Fortress Biotech, Inc.FBIO · Entity 6822 | Director | January 01, 2026 | January 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Fortress Biotech, Inc.
Report date January 01, 2026 · Filed January 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| common stock, par value $0.001SEC Table I · non-derivative | Direct | 192,397 |
Reported balance
After 2026-01-01 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-01-01 · Grant · Acquired 27,322 · Balance 192,397 F1: The Reporting Person was granted 27,322 shares of restricted stock pursuant to the Issuer's 2013 Stock Incentive Plan, as amended. One-third of the shares will vest on each of January 1, 2027, 2028, and 2029, subject to continued service. The Reporting Person elected to defer 100% of these restricted shares pursuant to the Issuer's Deferred Compensation Plan for Directors and instead received deferred share units that are subject to the same vesting conditions. Vested deferred shares will be delivered to the Reporting Person in January of the year following the Reporting Person's termination of service, or earlier upon their death or change in control of the Issuer. F2: Total holdings include 76,705 shares underlying deferred restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person was granted 27,322 shares of restricted stock pursuant to the Issuer's 2013 Stock Incentive Plan, as amended. One-third of the shares will vest on each of January 1, 2027, 2028, and 2029, subject to continued service. The Reporting Person elected to defer 100% of these restricted shares pursuant to the Issuer's Deferred Compensation Plan for Directors and instead received deferred share units that are subject to the same vesting conditions. Vested deferred shares will be delivered to the Reporting Person in January of the year following the Reporting Person's termination of service, or earlier upon their death or change in control of the Issuer.
F2: Total holdings include 76,705 shares underlying deferred restricted stock units.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
PARDES BIOSCIENCES, INC.
Report date August 31, 2023 · Filed August 31, 2023
Section 16 reporting ended · disclosed 2023-08-31. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-08-31 transaction · row 1
1 source rowRow 1 · 2023-08-31 · Other · Disposed 200,000 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, MediPacific, Inc. (Parent) and MediPacific Sub, Inc., a wholly-owned subsidiary of Parent (Purchaser), dated as of July 16, 2023 (Merger Agreement), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of August 31, 2023 (Effective Time). F2: Pursuant to the terms of the Merger Agreement and Purchaser's offer to purchase, the shares of common stock were tendered to Purchaser in consideration for a per share price of (i) $2.13 in cash, net of applicable taxes and without interest, and (ii) one non-transferable contractual contingent value right. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 0 |
Reported balance
After 2023-08-31 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2023-08-31 · Other · Disposed 1,163,861 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, MediPacific, Inc. (Parent) and MediPacific Sub, Inc., a wholly-owned subsidiary of Parent (Purchaser), dated as of July 16, 2023 (Merger Agreement), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of August 31, 2023 (Effective Time). F2: Pursuant to the terms of the Merger Agreement and Purchaser's offer to purchase, the shares of common stock were tendered to Purchaser in consideration for a per share price of (i) $2.13 in cash, net of applicable taxes and without interest, and (ii) one non-transferable contractual contingent value right. F3: Shares beneficially owned by JJL Pardes, LLC, of which the Reporting Person is the sole managing member. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.87 · Expires 2033-05-31 | Direct | 0 |
Reported balance
After 2023-08-31 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-08-31 · Disposition to issuer · Disposed 37,500 · Balance 0 F4: On July 16, 2023, the Issuer's Board of Directors vested in full each option to purchase shares granted under an Issuer equity plan (each, a Company Stock Option) that was outstanding and unvested as of that date. As of the Effective Time, each in-the-money Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled in-the-money Company Stock Option was entitled to receive, in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings and without interest) equal to the product of (x) the total number of shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess of $2.13 over the applicable exercise price per share under such Company Stock Option and (ii) one contingent value right for each share subject thereto. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.80 · Expires 2031-12-22 | Direct | 0 |
Reported balance
After 2023-08-31 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-08-31 · Disposition to issuer · Disposed 75,000 · Balance 0 F5: On July 16, 2023, the Issuer's Board of Directors vested in full each unvested Company Stock Option. Pursuant to the Merger Agreement, each Company Stock Option that was not in the money as of the Effective Time was cancelled for no consideration at the Effective Time. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.21 · Expires 2032-06-07 | Direct | 0 |
Reported balance
After 2023-08-31 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2023-08-31 · Disposition to issuer · Disposed 37,500 · Balance 0 F5: On July 16, 2023, the Issuer's Board of Directors vested in full each unvested Company Stock Option. Pursuant to the Merger Agreement, each Company Stock Option that was not in the money as of the Effective Time was cancelled for no consideration at the Effective Time. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, MediPacific, Inc. (Parent) and MediPacific Sub, Inc., a wholly-owned subsidiary of Parent (Purchaser), dated as of July 16, 2023 (Merger Agreement), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of August 31, 2023 (Effective Time).
F2: Pursuant to the terms of the Merger Agreement and Purchaser's offer to purchase, the shares of common stock were tendered to Purchaser in consideration for a per share price of (i) $2.13 in cash, net of applicable taxes and without interest, and (ii) one non-transferable contractual contingent value right.
F3: Shares beneficially owned by JJL Pardes, LLC, of which the Reporting Person is the sole managing member.
F4: On July 16, 2023, the Issuer's Board of Directors vested in full each option to purchase shares granted under an Issuer equity plan (each, a Company Stock Option) that was outstanding and unvested as of that date. As of the Effective Time, each in-the-money Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled in-the-money Company Stock Option was entitled to receive, in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings and without interest) equal to the product of (x) the total number of shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess of $2.13 over the applicable exercise price per share under such Company Stock Option and (ii) one contingent value right for each share subject thereto.
F5: On July 16, 2023, the Issuer's Board of Directors vested in full each unvested Company Stock Option. Pursuant to the Merger Agreement, each Company Stock Option that was not in the money as of the Effective Time was cancelled for no consideration at the Effective Time.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 01, 2026 Filed Jan 5, 2026 16:30 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | Grantcommon stock, par value $0.001 | 27,322 | $0.00 | $0.00 |
DisclosureSEC source: 0001172659-26-000002 · form4-01052026_040120.xml · nonDerivative · entry 1 LOBELL J JAY · CIK 0001172659 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 192,397 F1 · shares: The Reporting Person was granted 27,322 shares of restricted stock pursuant to the Issuer's 2013 Stock Incentive Plan, as amended. One-third of the shares will vest on each of January 1, 2027, 2028, and 2029, subject to continued service. The Reporting Person elected to defer 100% of these restricted shares pursuant to the Issuer's Deferred Compensation Plan for Directors and instead received deferred share units that are subject to the same vesting conditions. Vested deferred shares will be delivered to the Reporting Person in January of the year following the Reporting Person's termination of service, or earlier upon their death or change in control of the Issuer. F2 · balance_after: Total holdings include 76,705 shares underlying deferred restricted stock units. Read SEC document |
| January 01, 2025 Filed Jan 3, 2025 16:28 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | Grantcommon stock, par value $0.001 | 49,383 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-000444 · form4-01032025_090127.xml · nonDerivative · entry 1 LOBELL J JAY · CIK 0001172659 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 165,075 F1 · shares: The Reporting Person was granted 49,383 shares of restricted stock pursuant to the Issuer's 2013 Stock Incentive Plan, as amended. One-third of the shares will vest on each of January 1, 2026, 2027, and 2028, subject to continued service. The reporting person elected to defer 100% of these restricted shares pursuant to the Issuer's Deferred Compensation Plan for Directors and instead received deferred share units that are subject to the same vesting conditions. Vested deferred shares will be delivered to the Reporting Person in January of the year following the Reporting Person's termination of service, or earlier upon their death or change in control of the Issuer. F2 · balance_after: Total holdings include 49,383 shares underlying deferred restricted stock units. Read SEC document |
| January 01, 2024 Filed Jan 3, 2024 16:52 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | GrantCOMMON STOCK, PAR VALUE $0.001 | 6,666 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-000912 · tm241755-7_4seq1.xml · nonDerivative · entry 1 LOBELL J JAY · CIK 0001172659 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 115,692 F1 · shares: Effective October 10, 2023, the Issuer effected a one-for-fifteen reverse stock split of its common stock (the "Reverse Split"). The amount of common stock reflected on this Form 4 has been adjusted to reflect the Reverse Split. F2 · shares: One-third of the shares will vest on each of January 1, 2025, 2026, and 2027, subject to continued service. Read SEC document |
| August 31, 2023 Filed Aug 31, 2023 14:45 UTC | PARDES BIOSCIENCES, INC. PRDS · Entity 110063 | Disposition to issuerStock Option (Right to Buy) · Derivative | 37,500 | Not disclosed Strike: $5.21 | Not disclosed |
DisclosureSEC source: 0001209191-23-047825 · doc4.xml · derivative · entry 5 LOBELL J JAY · CIK 0001172659 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 37,500 shares Expires 2032-06-07 F5 · price: On July 16, 2023, the Issuer's Board of Directors vested in full each unvested Company Stock Option. Pursuant to the Merger Agreement, each Company Stock Option that was not in the money as of the Effective Time was cancelled for no consideration at the Effective Time. F5 · derivative.exercise_date: On July 16, 2023, the Issuer's Board of Directors vested in full each unvested Company Stock Option. Pursuant to the Merger Agreement, each Company Stock Option that was not in the money as of the Effective Time was cancelled for no consideration at the Effective Time. F5 · derivative.expiration_date: On July 16, 2023, the Issuer's Board of Directors vested in full each unvested Company Stock Option. Pursuant to the Merger Agreement, each Company Stock Option that was not in the money as of the Effective Time was cancelled for no consideration at the Effective Time. Read SEC document |
| August 31, 2023 Filed Aug 31, 2023 14:45 UTC | PARDES BIOSCIENCES, INC. PRDS · Entity 110063 | Disposition to issuerStock Option (Right to Buy) · Derivative | 75,000 | Not disclosed Strike: $9.80 | Not disclosed |
DisclosureSEC source: 0001209191-23-047825 · doc4.xml · derivative · entry 4 LOBELL J JAY · CIK 0001172659 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 75,000 shares Expires 2031-12-22 F5 · price: On July 16, 2023, the Issuer's Board of Directors vested in full each unvested Company Stock Option. Pursuant to the Merger Agreement, each Company Stock Option that was not in the money as of the Effective Time was cancelled for no consideration at the Effective Time. F5 · derivative.exercise_date: On July 16, 2023, the Issuer's Board of Directors vested in full each unvested Company Stock Option. Pursuant to the Merger Agreement, each Company Stock Option that was not in the money as of the Effective Time was cancelled for no consideration at the Effective Time. F5 · derivative.expiration_date: On July 16, 2023, the Issuer's Board of Directors vested in full each unvested Company Stock Option. Pursuant to the Merger Agreement, each Company Stock Option that was not in the money as of the Effective Time was cancelled for no consideration at the Effective Time. Read SEC document |
| August 31, 2023 Filed Aug 31, 2023 14:45 UTC | PARDES BIOSCIENCES, INC. PRDS · Entity 110063 | Disposition to issuerStock Option (Right to Buy) · Derivative | 37,500 | Not disclosed Strike: $1.87 | Not disclosed |
DisclosureSEC source: 0001209191-23-047825 · doc4.xml · derivative · entry 3 LOBELL J JAY · CIK 0001172659 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 37,500 shares Expires 2033-05-31 F4 · price: On July 16, 2023, the Issuer's Board of Directors vested in full each option to purchase shares granted under an Issuer equity plan (each, a Company Stock Option) that was outstanding and unvested as of that date. As of the Effective Time, each in-the-money Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled in-the-money Company Stock Option was entitled to receive, in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings and without interest) equal to the product of (x) the total number of shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess of $2.13 over the applicable exercise price per share under such Company Stock Option and (ii) one contingent value right for each share subject thereto. F4 · derivative.exercise_date: On July 16, 2023, the Issuer's Board of Directors vested in full each option to purchase shares granted under an Issuer equity plan (each, a Company Stock Option) that was outstanding and unvested as of that date. As of the Effective Time, each in-the-money Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled in-the-money Company Stock Option was entitled to receive, in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings and without interest) equal to the product of (x) the total number of shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess of $2.13 over the applicable exercise price per share under such Company Stock Option and (ii) one contingent value right for each share subject thereto. F4 · derivative.expiration_date: On July 16, 2023, the Issuer's Board of Directors vested in full each option to purchase shares granted under an Issuer equity plan (each, a Company Stock Option) that was outstanding and unvested as of that date. As of the Effective Time, each in-the-money Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled in-the-money Company Stock Option was entitled to receive, in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings and without interest) equal to the product of (x) the total number of shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess of $2.13 over the applicable exercise price per share under such Company Stock Option and (ii) one contingent value right for each share subject thereto. Read SEC document |
| August 31, 2023 Filed Aug 31, 2023 14:45 UTC | PARDES BIOSCIENCES, INC. PRDS · Entity 110063 | OtherCommon Stock | 1,163,861 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-047825 · doc4.xml · nonDerivative · entry 2 LOBELL J JAY · CIK 0001172659 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 0 F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, MediPacific, Inc. (Parent) and MediPacific Sub, Inc., a wholly-owned subsidiary of Parent (Purchaser), dated as of July 16, 2023 (Merger Agreement), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of August 31, 2023 (Effective Time). F2 · price: Pursuant to the terms of the Merger Agreement and Purchaser's offer to purchase, the shares of common stock were tendered to Purchaser in consideration for a per share price of (i) $2.13 in cash, net of applicable taxes and without interest, and (ii) one non-transferable contractual contingent value right. F3 · ownership.nature: Shares beneficially owned by JJL Pardes, LLC, of which the Reporting Person is the sole managing member. Read SEC document |
| August 31, 2023 Filed Aug 31, 2023 14:45 UTC | PARDES BIOSCIENCES, INC. PRDS · Entity 110063 | OtherCommon Stock | 200,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-047825 · doc4.xml · nonDerivative · entry 1 LOBELL J JAY · CIK 0001172659 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, MediPacific, Inc. (Parent) and MediPacific Sub, Inc., a wholly-owned subsidiary of Parent (Purchaser), dated as of July 16, 2023 (Merger Agreement), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of August 31, 2023 (Effective Time). F2 · price: Pursuant to the terms of the Merger Agreement and Purchaser's offer to purchase, the shares of common stock were tendered to Purchaser in consideration for a per share price of (i) $2.13 in cash, net of applicable taxes and without interest, and (ii) one non-transferable contractual contingent value right. Read SEC document |
| June 01, 2023 Filed Jun 2, 2023 16:07 UTC | PARDES BIOSCIENCES, INC. PRDS · Entity 110063 | GrantStock Option (Right to Buy) · Derivative | 37,500 | $0.00 Strike: $1.87 | $0.00 |
DisclosureSEC source: 0001209191-23-033667 · doc4.xml · derivative · entry 1 LOBELL J JAY · CIK 0001172659 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,500 Underlying: Common Stock · 37,500 shares Expires 2033-05-31 F1 · derivative.exercise_date: Subject to the reporting person's continued service to the Issuer on each applicable vesting date, the option vests as to 1/12 of the total award on each monthly anniversary of the Grant Date; provided, however, that notwithstanding the monthly vesting schedule, the options shall vest in full upon the earlier of (i) the one-year anniversary of the Grant Date or (ii) the date of the next annual meeting of the stockholders. Read SEC document |
| February 10, 2023 Filed Feb 14, 2023 16:07 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | PurchaseCOMMON STOCK, PAR VALUE $0.001 | 299,401 | $0.84 | $249,999.84 |
DisclosureSEC source: 0001104659-23-021607 · tm236803-2_4seq1.xml · nonDerivative · entry 1 LOBELL J JAY · CIK 0001172659 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,635,401 Read SEC document |
| January 01, 2023 Filed Jan 4, 2023 21:25 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | GrantCOMMON STOCK, PAR VALUE $0.001 | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-001097 · tm231728-4_4seq1.xml · nonDerivative · entry 1 LOBELL J JAY · CIK 0001172659 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,336,000 F1 · shares: One-third of the shares will vest on each of January 1, 2024, 2025 and 2026, subject to continued service. Read SEC document |
| July 19, 2022 Filed Jul 21, 2022 16:16 UTC | PARDES BIOSCIENCES, INC. PRDS · Entity 110063 | OtherCommon Stock | 1,163,861 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-042848 · doc4.xml · nonDerivative · entry 3 LOBELL J JAY · CIK 0001172659 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By JJL Pardes, LLC Disclosed balance after: 1,163,861 F3 · kind: The reported transaction represents the acquisition by JJL Pardes, LLC of the securites listed in this row through a pro rata distribution made by GMF Pardes, LLC. The reporting person is the sole managing member of JJL Pardes, LLC. Read SEC document |
| July 19, 2022 Filed Jul 21, 2022 16:16 UTC | PARDES BIOSCIENCES, INC. PRDS · Entity 110063 | OtherCommon Stock | 200,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-042848 · doc4.xml · nonDerivative · entry 2 LOBELL J JAY · CIK 0001172659 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 F2 · kind: The reported transaction represents the acquisition by the reporting person of direct beneficial ownership of the securites listed in this row through a pro rata distribution made by GMF Pardes, LLC. Read SEC document |
| July 19, 2022 Filed Jul 21, 2022 16:16 UTC | PARDES BIOSCIENCES, INC. PRDS · Entity 110063 | OtherCommon Stock | 3,591,265 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-042848 · doc4.xml · nonDerivative · entry 1 LOBELL J JAY · CIK 0001172659 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By GMF Pardes LLC Disclosed balance after: 0 F1 · kind: The reported transaction was a pro rata distribution made by GMF Pardes, LLC. At the time of the distribution and as of the date hereof, the reporting person was one of 3 managing members of GMF Pardes, LLC. The reporting person disclaims beneficial ownership of the shares reported in this row except to the extent of his pecuniary interest therein. Read SEC document |
| June 08, 2022 Filed Jun 10, 2022 16:28 UTC | PARDES BIOSCIENCES, INC. PRDS · Entity 110063 | GrantStock Option (Right to Buy) · Derivative | 37,500 | $0.00 Strike: $5.21 | $0.00 |
DisclosureSEC source: 0001209191-22-035903 · doc4.xml · derivative · entry 1 LOBELL J JAY · CIK 0001172659 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,500 Underlying: Common Stock · 37,500 shares Expires 2032-06-07 F1 · derivative.exercise_date: Subject to the reporting person's continued service to the Issuer on each applicable vesting date, the option vests as to 1/12 of the total award on each monthly anniversary of the Grant Date; provided, however, that notwithstanding the monthly vesting schedule, the options shall vest in full upon the earlier of (i) the one-year anniversary of the Grant Date or (ii) the date of the next annual meeting of the stockholders. Read SEC document |
| January 01, 2022 Filed Apr 29, 2022 16:18 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | GrantCommon Stock, par value $0.001 | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-053578 · tm2213913-3_4seq1.xml · nonDerivative · entry 1 LOBELL J JAY · CIK 0001172659 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,236,000 F1 · shares: One-third of the shares will vest on each of January 1, 2023, 2024 and 2025, subject to continued service. Read SEC document |
| December 23, 2021 Filed Dec 28, 2021 16:30 UTC | PARDES BIOSCIENCES, INC. PRDS · Entity 110063 | GrantStock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $9.80 | $0.00 |
DisclosureSEC source: 0000899243-21-049932 · doc4.xml · derivative · entry 1 LOBELL J JAY · CIK 0001172659 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2031-12-22 F1 · derivative.exercise_date: This option shall vest in substantially equal monthly installments over three years, subject to a continued service relationship. The vested shares subject to such option shall be exercisable upon the effectiveness of the Issuer's registration statement on Form S-8, registering the shares of the Issuer's 2021 Stock Option and Incentive Plan with the U.S. Securities and Exchange Commission. Read SEC document |
| January 01, 2021 Filed Apr 9, 2021 17:23 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | GrantCommon Stock, par value $0.001 | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-048827 · tm219139d4_4.xml · nonDerivative · entry 1 LOBELL J JAY · CIK 0001172659 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,136,000 F1 · shares: One-third of the shares will vest on each of January 1, 2022, 2023 and 2024, subject to continued service. Read SEC document |
| January 01, 2020 Filed Mar 13, 2020 16:07 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | GrantCommon Stock, par value $0.001 | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-033113 · tm2011481-4_form4.xml · nonDerivative · entry 1 LOBELL J JAY · CIK 0001172659 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,036,000 F1 · shares: One-third of the shares will vest on each of January 1, 2021, 2022 and 2023, subject to continued service. Read SEC document |
| January 01, 2019 Filed Apr 12, 2019 16:09 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | GrantCommon Stock | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-19-019497 · tv516219_4.xml · nonDerivative · entry 1 LOBELL J JAY · CIK 0001172659 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 936,000 F1 · shares: One-third of the shares will vest on each of January 1, 2020, 2021 and 2022, subject to continued service. Read SEC document |
| January 01, 2018 Filed Nov 30, 2018 17:28 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | GrantCommon Stock | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-18-062678 · tv495940_4.xml · nonDerivative · entry 1 LOBELL J JAY · CIK 0001172659 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 786,000 F1 · shares: One-third of the shares will vest on each of January 1, 2019, 2020, and 2021, subject to continued service. Read SEC document |
| January 01, 2017 Filed Jan 24, 2017 19:01 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | GrantCommon Stock, par value $0.001 | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001638599-17-000108 · doc4_4431.xml · nonDerivative · entry 1 LOBELL J JAY · CIK 0001172659 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 686,000 F1 · shares: One-third of the shares will vest on each of January 1, 2018, 2019 and 2020, and subject to continued service on the board of directors. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.